TWA
RLMD icon

TCI Wealth Advisors’s Relmada Therapeutics RLMD Stock Holding History

TCI Wealth Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,077
Closed -$3.76K – 2615
2022
Q4 		$3.76K Buy
+1,077
New +$9.46K ﹤0.01% 1717

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCI Wealth Advisors's RLMD Position: Q1 2023 in Review

TCI Wealth Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 1,077 shares — an estimated $3.76K sold.

TCI Wealth Advisors first reported a position in RLMD in Q4 2022 and held it in 1 quarter. The position peaked at $3.76K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • TCI Wealth Advisors reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 1,077 Relmada Therapeutics shares in Q1 2023, an estimated $3.76K.
  • TCI Wealth Advisors first reported a position in Relmada Therapeutics in Q4 2022 and held it in 1 quarter.
  • TCI Wealth Advisors's Relmada Therapeutics position peaked at $3.76K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on TCI Wealth Advisors's 13F filing for Q1 2023, filed 3 May 2023.